Cathepsin K (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Cathepsin K (UniProt P43235), expressed in HEK293 cells. Cysteine protease used in bone resorption assays, inhibitor IC50 determination, substrate cleavage studies, and antibody validation.
Expression system
HEK293
Cat. #
REC-CathepsinK

In stock

SKU
REC-CathepsinK
$498.00

Target Overview

Cathepsin K (UniProt P43235; gene CTSK) is a lysosomal cysteine protease of the papain superfamily, classified as EC 3.4.22.38. The mature human protein spans 329 amino acids and is expressed at particularly high levels in osteoclasts, where it is the principal collagenolytic enzyme responsible for degrading type I collagen and other extracellular matrix components during bone resorption. Beyond skeletal biology, Cathepsin K displays potent endoprotease activity against fibrinogen at acidic pH and participates in the limited proteolysis of thyroglobulin required for thyroxine (T4) release in the thyroid follicle lumen. This recombinant is produced in HEK293 mammalian cells, a system that supports the N-linked glycosylation and disulfide-bond formation characteristic of the native lysosomal enzyme. Mammalian expression is particularly relevant for Cathepsin K because correct folding of the active site is essential for its cysteine protease activity and for generating meaningful inhibitor potency data. Researchers use this recombinant in three principal contexts. First, in enzymatic activity assays — typically fluorogenic substrates such as Z-Phe-Arg-AMC or Z-Leu-Arg-AMC at pH 5.5 — to confirm lot-to-lot activity and establish assay baselines. Second, in inhibitor IC50 determinations, where the defined, recombinant source ensures reproducible enzyme concentrations across compound screening runs. Third, as a positive-control antigen for Western blot and IHC antibody validation: researchers using this recombinant for that purpose can pair it with the matched Triple Point Biologics antibody (catalog SKU RP-CathepsinK), which has been validated for both applications. Species reactivity is validated for human and predicted for mouse, rat, pan, monkey, dog, and pig orthologues.

Background

Cathepsin K (CTSK, EC 3.4.22.38) is a lysosomal cysteine protease originally identified in osteoclasts and subsequently characterised as the dominant mammalian collagenase acting at the acidic pH of the bone-resorption lacuna. Unlike matrix metalloproteinases, Cathepsin K cleaves native triple-helical type I and type II collagens at multiple sites under acidic conditions, making it the primary effector of osteoclast-mediated bone matrix degradation. Its substrates extend beyond collagen to include fibronectin, osteopontin, osteonectin, fibrinogen, and — in the thyroid — thyroglobulin, reflecting the enzyme's broader role in extracellular matrix remodelling across tissues. In published basic research, Cathepsin K expression is routinely used as a transcriptional and protein-level marker of osteoclast differentiation in RANKL-stimulated osteoclastogenesis models. Multiple recent studies demonstrate this approach: Jiang Y et al. (2026, J Cell Mol Med, PMID 42322165) quantified CTSK mRNA and protein to confirm that solasodine attenuates RANKL-induced osteoclastogenesis; Zhan Y et al. (2026, Pathol Res Pract, PMID 42320353) similarly assessed Cathepsin K as part of an osteoclast-marker panel when characterising isoorientin's effects on the ROS/PPARγ/NF-κB axis. These experimental designs, in which a defined recombinant standard anchors Western blot quantification and antibody specificity controls, represent a common and well-established use of recombinant Cathepsin K. Beyond osteoclast biology, Cathepsin K is studied as a research target in osteoporosis models (including ovariectomy-induced bone loss), bone metastasis, and thyroid hormone biosynthesis. Because the enzyme requires an acidic, reducing environment for full activity, in vitro assay conditions — typically pH 5.0–6.0 with DTT or TCEP as activating reductant — must be matched carefully to the physiological lysosomal context. The HEK293-expressed recombinant described here retains the glycosylation pattern of the native protein and can be activated under standard reducing-acidic buffer conditions prior to use in substrate cleavage or inhibitor competition experiments. Researchers investigating small-molecule or peptide-based inhibitors of Cathepsin K should note that the enzyme is susceptible to irreversible inhibition by E-64 and related epoxide inhibitors, providing a useful negative-control condition for activity-assay validation. Recombinant Cathepsin K is also used in mass spectrometry-based substrate identification workflows where a defined, homogeneous enzyme preparation is essential for confident peptide assignment.

Applications

  • Fluorogenic substrate cleavage assay (Z-Phe-Arg-AMC or Z-Leu-Arg-AMC) at pH 5.5 to confirm enzymatic activity and establish assay baselines
  • Inhibitor IC50 determination in competitive or time-dependent inhibition formats against small-molecule Cathepsin K inhibitors
  • Antibody validation positive control for Western blot, paired with Triple Point Biologics antibody RP-CathepsinK
  • RANKL-induced osteoclastogenesis marker validation — recombinant standard for quantitative Western blot of CTSK in differentiated osteoclast lysates
  • Substrate specificity profiling and peptide-library screening to map the Cathepsin K cleavage motif
  • Mass spectrometry-based substrate identification using recombinant enzyme incubated with complex extracellular matrix preparations
  • Enzymatic kinetics (Km, kcat, kcat/Km) determination with defined recombinant enzyme concentrations
  • E-64 or cystatin-based inhibitor validation as a negative-control condition in activity-assay development

References

  1. Jiang Y et al. Solasodine, a Natural Steroidal Alkaloid, Attenuates RANKL-Induced Osteoclastogenesis and Bone Resorption: A Study Based on Network Pharmacology and Experimental Validation. J Cell Mol Med. 2026. doi:10.1111/jcmm.71253. PMID: 42322165.
  2. Zhan Y et al. Isoorientin inactivated osteoclasts through inhibition of ROS/PPARγ/NF-κB signaling pathway in osteoporosis. Pathol Res Pract. 2026. doi:10.1016/j.prp.2026.156589. PMID: 42320353.
  3. Kim S et al. Bisphosphonate zoledronic acid blocks secretory autophagy and inhibits bone resorptive functions in osteoclasts. Autophagy. 2026. doi:10.1080/15548627.2026.2691880. PMID: 42316434.
  4. Fu M et al. Recombinant LGR4 extracellular domain attenuates osteoclastogenesis and prevents bone metastasis via RANKL inhibition. J Bone Oncol. 2026. doi:10.1016/j.jbo.2026.100768. PMID: 42291126.
  5. Zhang X et al. Koumine inhibits osteoclastogenesis and prevents ovariectomy-induced bone loss via suppression of the MAPK signaling pathways. Sci Rep. 2026. doi:10.1038/s41598-026-57325-4. PMID: 42288612.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Lysosome

Frequently Asked Questions

What molecular weight does recombinant Cathepsin K run at on SDS-PAGE and Western blot?

The mature processed form of human Cathepsin K (residues 115–329 after signal peptide and propeptide removal) has a predicted MW of ~23 kDa; however, N-linked glycosylation from HEK293 expression typically shifts the observed band to ~27–30 kDa under denaturing SDS-PAGE conditions. Under reducing conditions a single band is expected in that range at >90% purity. If you are running a non-reducing gel, note that the two conserved disulfide bonds will alter migration slightly. Plan your ladder range accordingly — a 10–50 kDa range covers both the glycosylated and deglycosylated forms.

What is the processing state of this recombinant Cathepsin K — is it the zymogen or the mature active form?

This product is supplied as the mature, active two-chain form of Cathepsin K, not the full-length zymogen. The 38-amino-acid signal peptide and the ~62-residue propeptide (which acts as an endogenous inhibitor at neutral pH) have been removed during HEK293 processing. What you receive is the catalytically competent mature enzyme corresponding to residues 115–329 of UniProt P43235. No additional activation step is required before use. This is especially relevant for activity assays — you can proceed directly from thaw to assay without preincubation with reducing agent alone, though DTT is still recommended to ensure active-site cysteine (Cys139) is fully reduced.

What substrates does Cathepsin K cleave and what fluorogenic substrate should I use for an activity assay?

Cathepsin K efficiently cleaves type I collagen, fibrinogen, and thyroglobulin in vivo. For in vitro fluorogenic activity assays, Z-Leu-Arg-AMC (Cbz-Leu-Arg-7-amido-4-methylcoumarin) is the most widely used substrate for Cathepsin K, with Km values typically in the 5–20 µM range under acidic conditions. Z-Gly-Pro-Arg-AMC is also accepted. Avoid Z-Phe-Arg-AMC as the primary substrate — it is more selective for Cathepsin B and L and will underestimate Cathepsin K-specific activity. Monitor AMC release at Ex/Em 360/460 nm. Always include a no-enzyme blank and an E-64 inhibitor control to confirm cysteine protease-dependent signal.

What buffer conditions are optimal for Cathepsin K activity assays — pH, reducing agent, and temperature?

Cathepsin K has peak activity between pH 5.5 and 6.5, consistent with its lysosomal environment. A standard assay buffer of 50 mM sodium acetate pH 5.5, 5 mM DTT, 2.5 mM EDTA works well for fluorogenic substrate assays. DTT (or TCEP at 1–2 mM) is essential to maintain the catalytic Cys139 in the reduced, active state — omitting reducing agent will substantially reduce or abolish activity. Assay at 37°C for physiological relevance, or 25°C for slower, more controllable kinetics. Note that the storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is not the assay buffer; dilute the enzyme into activity assay buffer immediately before use.

What starting concentration of recombinant Cathepsin K should I use for an IC50 inhibitor screening assay?

For Z-Leu-Arg-AMC fluorogenic inhibitor screening, a Cathepsin K enzyme concentration of 1–5 nM in assay buffer (50 mM sodium acetate pH 5.5, 5 mM DTT, 2.5 mM EDTA) typically gives a robust signal window with substrate at 20–50 µM (well below saturating concentrations to keep conditions suitable for Ki determination). Pre-incubate enzyme with inhibitor for 15–30 minutes at 37°C before adding substrate to allow equilibration, particularly for slow-binding inhibitors such as odanacatib analogs. Run a substrate titration on your plate reader first to confirm linearity before committing compound libraries.

Can I use recombinant Cathepsin K as a positive control for Western blot with TPB's matched anti-Cathepsin K antibody?

Yes — this is a validated pairing. The matched antibody, SKU RP-CathepsinK (/anti-cathepsin-k-rabbit-polyclonal-antibody), is a rabbit polyclonal raised against human Cathepsin K and has been validated for Western blot using this recombinant protein as the positive control antigen in-house. Load 10–50 ng of REC-CathepsinK per lane alongside your cell lysates; the antibody reliably detects the ~27–30 kDa glycosylated band. Because TPB has validated this antibody–antigen pair from the same production batch, you get a predictable reference band without needing to source a separate standard — useful for antibody lot-to-lot comparisons and assay setup.

How much recombinant Cathepsin K should I load as a positive control for Western blot, and what band should I expect?

Load 10–50 ng per lane under reducing, denaturing conditions. At 10 ng, RP-CathepsinK detects a clear ~27–30 kDa band (glycosylated mature form) with minimal background on standard PVDF or nitrocellulose membranes after blocking with 5% non-fat milk in TBST. If your primary antibody concentration is at the lower end of the recommended range (e.g., 1:2000 dilution of RP-CathepsinK), loading 25–50 ng provides a stronger reference. Do not exceed 100 ng — overloading can cause band spreading and obscure endogenous signals in adjacent lysate lanes. Always run the recombinant in a dedicated lane rather than spiking into complex lysate.

How should I store and handle recombinant Cathepsin K after arrival to maintain activity — any freeze-thaw considerations?

Upon receipt, store at -20°C in the single-use aliquots as supplied. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) stabilizes the enzyme during freeze-thaw, but cysteine proteases are particularly sensitive to oxidation of the active-site thiol. Avoid repeated freeze-thaw cycles — activity loss of >20% has been reported after three cycles for similar cysteine proteases. If you anticipate daily use over one to two weeks, keep a working aliquot at 4°C with freshly added DTT (1–2 mM) and use within 7 days. Do not dilute in buffers containing heavy metals or iodoacetamide, both of which irreversibly alkylate Cys139.

Validation imagery coming soon

Western blot validation figures for REC-CathepsinK will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →